SOUBEIRAN CHOBET S.R.L. Listed by crypto24 Ransomware Group: Ransomware Claim — What’s Alleged & What To Do

SOUBEIRAN CHOBET S.R.L. was listed by the ransomware group crypto24 on or around 14 July 2025. Public reporting indicates the group claims to have carried out a ransomware attack that included the exfiltration of internal files. The number of people affected remains unknown, and independent confirmation of the full scope is limited at this stage. The listing matters because the organisation appears to operate in a regulated pharmaceutical context, where internal systems routinely hold sensitive operational, financial and research material.

What is known so far rests primarily on the group’s own leak-site claim rather than on detailed official disclosures. No independent verification of the volume or exact contents has been made public, and the company has not issued a comprehensive public statement that expands on the facts available.

Inside the incident

According to the available record, SOUBEIRAN CHOBET S.R.L. was listed by crypto24 as a ransomware victim on 14 July 2025. The group asserts that it exfiltrated more than 300 GB of data from internal servers. The claimed material includes full databases, among them a Microsoft Dynamics GP database, financial and accounting records, HR files, inventory logs, production-process information, customer contracts, complaint records, data-analytics and marketing materials, plus research-and-development and quality-control datasets. Those datasets are described as encompassing HPLC/FASE MOVIL outputs, experimental protocols, specialised pharmaceutical formulations, master batch records, ANMAT/FDA CTDs, product-recall logs, GMP audit results and deviation reports.

Public detail on the precise timing of the intrusion, the initial access method, the encryption status of systems, or any ransom demand is undisclosed. The number of individuals whose personal information may have been involved is listed as unknown. No confirmed forensic timeline or independent technical analysis has been released in the material available for this report.

The group behind it: crypto24

crypto24 is a ransomware operation that follows the now-familiar double-extortion model: data is stolen before systems are encrypted, and the threat of public release is used to pressure victims. Groups of this type typically maintain leak sites where they post victim names and sample files, then escalate to full data dumps if negotiations fail. crypto24 has been observed listing organisations across multiple sectors and geographies, often claiming large volumes of corporate data. Its public communications are generally limited to the claims posted on its site; those claims should be treated as unverified assertions until corroborated by the victim or by independent investigators.

In this instance the group claims to have taken more than 300 GB of material from SOUBEIRAN CHOBET S.R.L. No further statements from crypto24 specifically addressing this victim beyond the listing and the accompanying description have been reported in the available facts.

SOUBEIRAN CHOBET S.R.L. and its sector

SOUBEIRAN CHOBET S.R.L. is a commercial entity whose internal systems, according to the group’s description, contain pharmaceutical-related records. Organisations of this kind typically operate under strict regulatory frameworks covering good manufacturing practice, product registration dossiers, quality control and supply-chain documentation. They commonly maintain enterprise resource-planning systems for finance and inventory, human-resources databases, customer and contract files, and research datasets that include analytical results and proprietary formulations.

A breach affecting such an organisation is consequential because the data held can include both commercially sensitive intellectual property and personal information belonging to employees, contractors or business partners. Regulatory filings and audit records also carry compliance implications if they become public or are misused.

What was likely exposed

The facts name the exposed material only through the group’s claim of “internal files exfiltrated in ransomware attack.” The accompanying description lists full databases (including Microsoft Dynamics GP), financials, accounting records, HR files, inventory logs, production processes, customer contracts, complaint records, analytics and marketing materials, and a range of R&D and QC datasets such as HPLC outputs, experimental protocols, pharmaceutical formulations, master batch records, ANMAT/FDA CTDs, recall logs, GMP audits and deviation reports. The claimed volume is over 300 GB.

Exact contents remain unconfirmed by independent sources. Organisations in the pharmaceutical sector ordinarily hold employee personal data, supplier and customer contact details, contractual terms, financial ledgers and proprietary technical documentation. Whether any of those categories were in fact taken, and in what completeness, cannot be stated as established fact on the basis of the current record.

Why it matters

For individuals whose information may have been present—employees, contractors or business contacts—the principal risks are identity misuse, targeted phishing and unsolicited contact that leverages knowledge of internal roles or relationships. Financial and contractual data can enable fraud or competitive harm. For the organisation itself, exposure of proprietary formulations, manufacturing know-how and regulatory dossiers can undermine competitive position and trigger regulatory scrutiny. Even if systems are restored, the continued existence of stolen copies creates ongoing uncertainty about secondary use or further dissemination.

Because the number of people affected is unknown and the precise data elements are unconfirmed, the practical impact cannot yet be quantified. The absence of public detail does not reduce the need for caution among those who have had dealings with the company.

If your data was in this claimed breach

If you have reason to believe your information may have been held by SOUBEIRAN CHOBET S.R.L., begin by monitoring financial and email accounts for unusual activity and enable multi-factor authentication wherever available. Consider placing fraud alerts with credit-reporting agencies if personal identifiers were likely involved. Review any recent communications that appear to reference internal company matters for signs of social-engineering attempts. Readers can also run a free exposure scan of their email address to check whether their information has already surfaced in known breach data sets. Official notifications from the organisation, if and when issued, should be treated as the primary source of guidance for next steps.

AICompiled with AI assistance from public sources and published under our editorial standards.